Home -> Law Blog Directory -> In-House Counsel Blogs -> Law Department Management
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
In-House Counsel
: Law Department ManagementThe odds you will reach settlement vary according to tryptophan and serotonin levels
By Rees Morrison
If you are in in-house litigator and you sit down to hammer out a settlement with your opponents over a meal, be sure to serve plenty of tryptophan.
It turns out that levels of serotonin, a brain chemical that seems to control our reactions to unfairness, depends on tryptophan levels, and together they influence how we view offers. According to Scientific Am., Aug. 2008 at 36, neurophysiology researchers found that subjects low in tryptophan, an ingredient the body needs to manufacture serotonin, were more likely to reject offers in an ultimatum game. In that game, one subject proposes how to divide a sum of money and the other subject either accepts or rejects. A rejection means that no one gets anything. Serotonin-deprived subjects were much more likely to reject offers than were normal subjects, full of tryptophan.
Full post as published by Law Department Management on July 27, 2008 (boomark / email).
Native American Farmers, Ranchers and USDA Reach Historic Settlement
Native American Farmers, Ranchers and USDA Reach Historic Settlement
US Reality TV Shows
Reach Tentative $4 Million Settlement
Insurers
Reach $80 Million Settlement with Merck over Vioxx
Air Pollution
Low Levels May Increase Stroke Risk
Herbal Medicines
Contain High Levels of Toxic Metals
Casper Halloween Figures
Recalled due to High Lead Levels

Factoring Company "Servicing" of Structured Settlements-Thought Leaders Butt Heads
Playing the Odds, Settlement or Trial
Zyprexa Makers, 32 States Reach $62M Settlement
Settlement Professional's Bombastic Premise is Inaccurate
Illinois AG, Foreclosure Rescue Operator Reach Settlement In Civil Suit
Vioxx Registration Deadline Passes: Merck Hopes 85% Take the Deal








